TFXNYSE

TELEFLEX INC

Surgical & Medical Instruments & Apparatus · DE · CIK 96943

Teleflex provides medical technology products that improve clinical benefits, patient safety, and reduce procedural costs

red 8-K · 90d🔥 High media attention

+ Watch View on EDGAR ↗

$5.78B

Market cap

$127.49

Last close

-1.8%

+4.8%

399K

Volume

Price · last 39 sessions+6.3%

May 4L $119.89 · H $135.75Jun 29

268

Total filings

Jun 26, 2026

Last filing

12/31

Fiscal year end

All 8-K · 162 10-Q · 43 10-K · 15 11-K · 15 DEF 14A · 15 SC 13G · 8 8-K/A · 4 424B5 · 3

What Changed

Risk factors · Feb 28, 2025 → Feb 27, 2026

30 added · 34 removed between the two most recent 10-Ks. The risks a company starts — or stops — disclosing are often the story.

Newly disclosed

In accordance with this strategy, on December 9, 2025, with the simultaneous execution of definitive agreements to sell our Acute Care and Interventional Urology businesses to Intersurgical® Ltd and the OEM business to Montagu and Kohlberg (collectively referred to as the "Strategic Divestitures").
Both transactions, which were approved by our Board of Directors, remain subject to certain closing adjustments, customary regulatory approvals and other closing conditions and are expected to be completed in the second half of 2026.
On January 8, 2026, we announced that Stuart Randle, a member of our board of directors, has been appointed Interim President and Chief Executive Officer, succeeding our prior Chairman, President and CEO, and that Dr.
The combined transaction total of Strategic Divestitures is $2.0 billion in cash, consisting of expected proceeds of approximately $1.5 billion for our OEM business and $530 million for our Acute Care and Interventional Urology businesses.
For instance, in the first quarter of 2026 we committed to a multi-year restructuring plan intended to eliminate stranded costs and improve our long‑term cost structure.
While we have realized some efficiencies from these initiatives, we may not realize the benefits of these or future initiatives to the extent we anticipated, particularly with respect to initiatives involving contingencies that are not completely within our control, such as the completion of acquisitions or divestitures.
These challenges include, without limitation, obtaining the regulatory approvals necessary for, and satisfying the closing conditions to, the transactions, and the diversion of management’s attention from ongoing business concerns to completing the transactions.
Then, both in the period before the transactions are consummated and thereafter, when we are operating a modified business, we may face 17 challenges in attracting, retaining and motivating key management and other employees; retaining existing, or attracting new, business and operational relationships, including with customers, distributors, suppliers, employees and other counterparties; maintaining our relationships with regulators; and potential negative reactions from the financial markets.
Further, our enhanced reliance in the wake of the disposition of the Acute Care, Interventional Urology and OEM businesses on a smaller suite of existing products and on future products may pose risks to our growth, and following the transactions, we will be a less diversified company than we are today, with a more limited business.
If the financial contribution from remaining legacy products and other products that we may acquire or develop in the future fails to replace lost contribution from the Acute Care, Interventional Urology and OEM businesses, or otherwise fail to meet expectations, our business, cash flows and results of operations could be adversely affected.
The continuation in a number of markets of weak economic growth, constricted credit, public sector austerity measures in response to public budget deficits and foreign currency volatility, particularly with respect to the euro, could have a material adverse effect on our results of operations, financial condition and liquidity. 19 Although we maintain allowances for doubtful accounts to cover the estimated losses which may occur when customers cannot make their required payments, we cannot assure that the loss rate will not increase in the future given the volatility in the worldwide economy.
If we are unable to identify a strong candidate for the position, or if our replacement CEO, interim or permanent, is unsuccessful at leading our company or is unable to articulate and execute our strategy and vision, it could have a material adverse effect on our business, financial condition, results of operations and cash flows.

No longer disclosed

For example, though their long-term impact remains uncertain, the increased use and the recent FDA approval of glucagon-like peptide 1 ("GLP-1") products for the treatment of chronic weight management has impacted the demand for bariatric surgery procedures and our Titan SGS product line acquired as part of our 2022 acquisition of Standard Bariatrics Inc. 14 In addition, the medical device industry is characterized by extensive product research and development and rapid technological advances.
If, due to such adverse changes, we are required to write down all or a significant part of our goodwill, our operating results would be negatively affected. 22 As described more fully in Item 7 and Note 8 to the consolidated financial statements of this Annual Report on Form 10-K, in connection with preparing the financial statements for the year ended December 31, 2024, we determined that the carrying value of the IU reporting unit exceeded its fair value, and we therefore recognized an impairment charge of $240 million in the goodwill impairment line in the Consolidated Statements of Income.
Continued adverse changes to macroeconomic conditions or our earnings forecasts would lead to additional goodwill impairment charges and such charges would negatively affect our results of operations.
Volume-based procurement and similar programs in China and other countries are likely to have an adverse impact on future results due to reduced pricing. 15 We are subject to extensive government regulation, which may require us to incur significant expenses to ensure compliance.
The continuation in a number of markets of weak economic growth, constricted credit, public sector austerity measures in response to public budget deficits and foreign currency volatility, particularly with respect to the euro, could have a material adverse effect on our results of operations, financial condition and liquidity.
Although we maintain allowances for doubtful accounts to cover the estimated losses which may occur when customers cannot make their required payments, we cannot assure that the loss rate will not increase in the future given the volatility in the worldwide economy.
The separation will be subject to the satisfaction of a number of customary conditions, including, but not limited to, the final approval from the Company’s Board of Directors, the filing and effectiveness of a registration statement on Form 10, the receipt of a favorable Internal Revenue Service ruling and tax opinion the Company’s tax advisor with respect to the tax-free nature of the separation, the satisfactory completion of financing arrangements and the receipt of any necessary regulatory approvals.
Additionally, it is complex in nature, and unanticipated developments or changes, including disruptions in general market conditions, changes in law or challenges in executing the separation of the two businesses, may affect our ability to complete the separation on the terms or on the timeline we announced, or at all.
The terms and conditions of the required regulatory authorizations and consents that are granted, if any, may also impose requirements, limitations or costs, or place restrictions on the conduct of the independent companies or impact our ability to complete the separation on the terms or timeline we announced, or at all.
If any of these factual representations or assumptions are, or become, untrue or incomplete in any material respect, an undertaking is not complied with, or the facts upon which the ruling and opinion are based are materially different from the actual facts relating to the separation, reliance on the ruling and opinion may be jeopardized.
If the separation was ultimately determined to be taxable for U.S. federal income tax purposes, we would incur a significant tax liability, while the distribution of shares of the new independent company to the Company’s stockholders would become taxable to them for U.S. federal income tax purposes and the new independent company could incur income tax liabilities as well.
In addition, even if the separation is tax-free for U.S. federal income tax purposes, the Company and the new independent company may incur state, local, non-U.S. and/or non-income taxes in connection with the separation, including as a result of the incorporation of the OECD’s Pillar Two global minimum tax framework into local country tax laws, which taxes may be significant.

In the News

🔥 High media attention

Coverage (30d): 15 reputable articles.

MarketWatchTeleflex Inc. stock underperforms Monday when compared to competitors16h ago MarketWatchTeleflex Inc. stock underperforms Friday when compared to competitors despite daily gains3d ago MarketWatchTeleflex Inc. stock outperforms competitors on strong trading day5d ago MarketWatchTeleflex Inc. stock underperforms Wednesday when compared to competitors12d ago MarketWatchTeleflex Inc. stock underperforms Tuesday when compared to competitors13d ago MarketWatchTeleflex Inc. stock underperforms Thursday when compared to competitors18d ago

Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗

Similar companies

Comparable business profile · signals at a glance

ICUIICU MEDICAL INC/DE$3.6B-0.2%AVNSAVANOS MEDICAL, INC.$1.2B-0.1%PENPenumbra Inc$12.5B-0.4%BAXBAXTER INTERNATIONAL INC🔥$10.8B-0.1%MMSIMERIT MEDICAL SYSTEMS INC$4.0B-2.3%ITGRInteger Holdings Corp$3.1B-2.8%